Barclays’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.4M | Buy |
1,338,482
+203,843
| +18% | +$2.92M | ﹤0.01% | 1122 |
|
|
2025
Q4 | $16.2M | Buy |
1,134,639
+165,117
| +17% | +$1.62M | ﹤0.01% | 1367 |
|
|
2025
Q3 | $7.64M | Sell |
969,522
-213,213
| -18% | -$1.52M | ﹤0.01% | 1869 |
|
|
2025
Q2 | $6.78M | Buy |
1,182,735
+546,637
| +86% | +$3.53M | ﹤0.01% | 1859 |
|
|
2025
Q1 | $5.19M | Sell |
636,098
-28,562
| -4% | -$264K | ﹤0.01% | 1881 |
|
|
2024
Q4 | $6.26M | Buy |
664,660
+32,955
| +5% | +$343K | ﹤0.01% | 1950 |
|
|
2024
Q3 | $6.75M | Buy |
631,705
+185,314
| +42% | +$2.02M | ﹤0.01% | 1796 |
|
|
2024
Q2 | $4.43M | Buy |
446,391
+97,454
| +28% | +$1M | ﹤0.01% | 1620 |
|
|
2024
Q1 | $4.11M | Sell |
348,937
-378,838
| -52% | -$4.84M | ﹤0.01% | 1999 |
|
|
2023
Q4 | $10.3M | Buy |
727,775
+315,339
| +76% | +$3.58M | ﹤0.01% | 1495 |
|
|
2023
Q3 | $5.02M | Buy |
412,436
+7,096
| +2% | +$91.5K | ﹤0.01% | 1313 |
|
|
2023
Q2 | $5.09M | Sell |
405,340
-51,810
| -11% | -$615K | ﹤0.01% | 1335 |
|
|
2023
Q1 | $5.07M | Buy |
457,150
+35,330
| +8% | +$435K | ﹤0.01% | 1533 |
|
|
2022
Q4 | $5.15M | Buy |
421,820
+16,299
| +4% | +$183K | ﹤0.01% | 1602 |
|
|
2022
Q3 | $4.23M | Buy |
405,521
+387,185
| +2,112% | +$4.31M | ﹤0.01% | 1266 |
|
|
2022
Q2 | $197K | Sell |
18,336
-88,882
| -83% | -$732K | ﹤0.01% | 3426 |
|
|
2022
Q1 | $1.01M | Sell |
107,218
-219,041
| -67% | -$2.05M | ﹤0.01% | 2382 |
|
|
2021
Q4 | $3.77M | Sell |
326,259
-125,879
| -28% | -$1.4M | ﹤0.01% | 1917 |
|
|
2021
Q3 | $4.32M | Buy |
452,138
+228,331
| +102% | +$2.34M | ﹤0.01% | 1730 |
|
|
2021
Q2 | $2.16M | Sell |
223,807
-207,946
| -48% | -$2.03M | ﹤0.01% | 2140 |
|
|
2021
Q1 | $4.27M | Buy |
431,753
+229,812
| +114% | +$3.56M | ﹤0.01% | 1651 |
|
|
2020
Q4 | $4.66M | Sell |
201,941
-238,687
| -54% | -$4.88M | ﹤0.01% | 1560 |
|
|
2020
Q3 | $6.22M | Sell |
440,628
-38,757
| -8% | -$565K | ﹤0.01% | 1275 |
|
|
2020
Q2 | $7.23M | Sell |
479,385
-81,956
| -15% | -$999K | 0.01% | 1137 |
|
|
2020
Q1 | $5.19M | Sell |
561,341
-162,566
| -22% | -$1.55M | ﹤0.01% | 1430 |
|
|
2019
Q4 | $7.05M | Buy |
723,907
+497,092
| +219% | +$4.55M | ﹤0.01% | 1678 |
|
|
2019
Q3 | $1.82M | Buy |
226,815
+77,517
| +52% | +$841K | ﹤0.01% | 2987 |
|
|
2019
Q2 | $1.86M | Buy |
149,298
+65,611
| +78% | +$833K | ﹤0.01% | 3008 |
|
|
2019
Q1 | $1.14M | Buy |
83,687
+59,341
| +244% | +$725K | ﹤0.01% | 3270 |
|
|
2018
Q4 | $233K | Sell |
24,346
-75,368
| -76% | -$828K | ﹤0.01% | 4469 |
|
|
2018
Q3 | $1.21M | Buy |
99,714
+85,854
| +619% | +$1.2M | ﹤0.01% | 3456 |
|
|
2018
Q2 | $216K | Sell |
13,860
-32,281
| -70% | -$488K | ﹤0.01% | 4653 |
|
|
2018
Q1 | $693K | Buy |
46,141
+14,135
| +44% | +$215K | ﹤0.01% | 3620 |
|
|
2017
Q4 | $460K | Buy |
32,006
+28,174
| +735% | +$387K | ﹤0.01% | 3921 |
|
|
2017
Q3 | $58K | Sell |
3,832
-6,564
| -63% | -$86.8K | ﹤0.01% | 5276 |
|
|
2017
Q2 | $105K | Buy |
10,396
+4,323
| +71% | +$34.8K | ﹤0.01% | 4865 |
|
|
2017
Q1 | $43K | Sell |
6,073
-217,699
| -97% | -$1.38M | ﹤0.01% | 5423 |
|
|
2016
Q4 | $1.11M | Buy |
223,772
+86,404
| +63% | +$598K | ﹤0.01% | 2643 |
|
|
2016
Q3 | $1.02M | Buy |
+137,368
| New | +$928K | ﹤0.01% | 2606 |
|
|
2016
Q2 | – | Sell |
-1,175
| Closed | -$9K | – | 6405 |
|
|
2016
Q1 | $9K | Sell |
1,175
-15,856
| -93% | -$112K | ﹤0.01% | 5503 |
|
|
2015
Q4 | $153K | Sell |
17,031
-15,919
| -48% | -$143K | ﹤0.01% | 4121 |
|
|
2015
Q3 | $429K | Buy |
32,950
+31,053
| +1,637% | +$487K | ﹤0.01% | 3490 |
|
|
2015
Q2 | $27K | Buy |
1,897
+783
| +70% | +$9.41K | ﹤0.01% | 5501 |
|
|
2015
Q1 | $11K | Buy |
1,114
+410
| +58% | +$3.61K | ﹤0.01% | 6173 |
|
|
2014
Q4 | $6K | Buy |
704
+563
| +399% | +$3.86K | ﹤0.01% | 6922 |
|
|
2014
Q3 | $1K | Sell |
141
-43,191
| -100% | -$226K | ﹤0.01% | 7498 |
|
|
2014
Q2 | $130K | Buy |
43,332
+42,019
| +3,200% | +$98.6K | ﹤0.01% | 5211 |
|
|
2014
Q1 | $2K | Buy |
1,313
+516
| +65% | +$1.29K | ﹤0.01% | 7399 |
|
|
2013
Q4 | $1K | Sell |
797
-1,346
| -63% | -$2.95K | ﹤0.01% | 7438 |
|
|
2013
Q3 | $4K | Sell |
2,143
-763
| -26% | -$1.92K | ﹤0.01% | 7033 |
|
|
2013
Q2 | $7K | Buy |
+2,906
| New | +$8.93K | ﹤0.01% | 7255 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Barclays's FOLD Position: Q1 2026 in Review
Barclays increased its Amicus Therapeutics (FOLD) stake by 18% in Q1 2026, buying an estimated $2.92M and bringing the position to 1,338,482 shares worth $19.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1122.
Barclays first reported a position in FOLD in Q2 2013 and has held it in 51 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Barclays held 1,338,482 shares of Amicus Therapeutics worth $19.4M as of Q1 2026.
- Barclays bought 203,843 Amicus Therapeutics shares in Q1 2026, an estimated $2.92M.
- Amicus Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1122 holding.
- Barclays first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 51 quarters since.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.